Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

Summary

The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal. QEL-001 is a product made from a patients own cells, which are genetically modified and designed to help the transplant recipient's body accept their donated liver and prevent their immune system from rejecting it once immune suppression is withdrawn.

Timeline

Start

2022-01-21

Primary completion

2026-02-25

Completion

2040-09

Drugs

Indications